



Financial Tear Sheet

Corporate Profile

Incyte's mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Primary IR Contact

Michael Booth, D.Phil.
Vice President, Investor Relations

Phone: 302.498.5914

Fax: 302.425.2707

E-mail: mbooth@incyte.com

Stock Performance

INCY (Common)

Exchange	NASDAQ (US Dollar)
Price	\$110.85
Change (%)	▼ 4.2 (3.65%)
Volume	2,174,260
52 Week Low	\$83.01
Market Cap	\$23,350,522,681
Rolling EPS	-0.76
PE Ratio	N/A

Shares Outstanding 210,649,731

Data as of September 22, 2017 4:00 p.m. ET



Recent Headlines

September 14, 2017

[Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis](#)

September 09, 2017

[Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with KEYTRUDA® \(pembrolizumab\) Underscore Durability of Response in Patients with Advanced Melanoma](#)

September 09, 2017

[Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA® \(pembrolizumab\) Underscore Durability of Response in Patients with Advanced Melanoma](#)

Data provided by Nasdaq. Minimum 15 minutes delayed.

Events

There are currently no events scheduled.